Technical Analysis for VTVT - vTv Therapeutics Inc.

Grade Last Price % Change Price Change
grade D 1.72 -1.15% -0.02
VTVT closed down 1.15 percent on Wednesday, September 18, 2019, on 7.64 times normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical VTVT trend table...

Date Alert Name Type % Chg
200 DMA Resistance Bearish 0.00%
Volume Surge Other 0.00%
Wide Range Bar Range Expansion 0.00%
Upper Bollinger Band Walk Strength 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Fell Below 200 DMA Bearish -1.15%
Upper Bollinger Band Walk Strength -1.15%

Older signals for VTVT ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
vTv Therapeutics Inc., a biopharmaceutical company, engages in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease includes azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials. The company's type 2 diabetes drug candidates comprise TTP399, an orally administered, liver-selective glucokinase activator, which is in a Phase IIb clinical trials; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor that has completed Phase I clinical trials. It is also developing HPP593, a functionally selective peroxisome proliferator-activated receptor delta agonist for the prevention of muscle weakness associated with prolonged mechanical ventilation and critical injury that has completed Phase Ib clinical trials; HPP737, an orally administered phosphodiesterase-4 inhibitor for the treatment of chronic obstructive pulmonary disease, psoriasis, and other inflammatory diseases, which has completed Phase Ib clinical trials; and HPP971, a Bach1 inhibitor, for the treatment of inflammation, autoimmune diseases, and diseases associated with oxidative stress, which is in Phase 1 clinical trials. The company has a license and research agreement with Calithera Biosciences, Inc. to research, develop, and commercialize its hexokinase II inhibitors for therapeutics, prophylactic, preventative, or diagnostic use. vTv Therapeutics Inc. was founded in 2015 and is headquartered in High Point, North Carolina.
Medicine Chemistry Biopharmaceutical Diseases Diabetes Autoimmune Diseases Inflammation Alzheimer's Disease Organic Chemistry Parkinson's Disease Psoriasis Inflammatory Diseases Chronic Obstructive Pulmonary Disease Pyridines Treatment Of Alzheimer's Disease Tyrosine Kinase Inhibitors Biotie Therapies Treatment Of Chronic Obstructive Pulmonary Disease Buparlisib Mechanical Ventilation Treatment Of Inflammation
Is VTVT a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 6.09
52 Week Low 0.75
Average Volume 356,152
200-Day Moving Average 1.7709
50-Day Moving Average 1.3951
20-Day Moving Average 1.4342
10-Day Moving Average 1.5396
Average True Range 0.1152
ADX 41.04
+DI 39.9218
-DI 6.8657
Chandelier Exit (Long, 3 ATRs ) 1.5844
Chandelier Exit (Short, 3 ATRs ) 1.6156
Upper Bollinger Band 1.7477
Lower Bollinger Band 1.1207
Percent B (%b) 0.96
BandWidth 43.717752
MACD Line 0.091
MACD Signal Line 0.0437
MACD Histogram 0.0473
Fundamentals Value
Market Cap 16.67 Million
Num Shares 9.69 Million
EPS -1.67
Price-to-Earnings (P/E) Ratio -1.03
Price-to-Sales 535.97
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.19
Resistance 3 (R3) 2.20 2.07 2.11
Resistance 2 (R2) 2.07 1.95 2.06 2.08
Resistance 1 (R1) 1.89 1.88 1.83 1.88 2.06
Pivot Point 1.76 1.76 1.72 1.75 1.76
Support 1 (S1) 1.58 1.64 1.52 1.57 1.38
Support 2 (S2) 1.45 1.57 1.44 1.36
Support 3 (S3) 1.27 1.45 1.33
Support 4 (S4) 1.26